PARTNER III A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients who have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement
Patients with severe aortic stenosis using Edwards SAPIEN 3 Transcatheter Heart Valve instead of surgery to treat aortic stenosis PARTNER 3
Sponsor: Edwards Lifesciences LLC
Enrolling: Male and Female Patients
IRB Number: AAAQ7114
U.S. Govt. ID: NCT026751144
Contact: Lauren Privitera: 212-342-3488 / lp2183@cumc.columbia.edu
Additional Study Information: This research study is for patients with severe aortic stenosis. Patients may be considered for this study if they have a diseased aortic heart valve and who are at low operative risk for standard (traditional) open-heart surgery for aortic valve replacement (TAVR).
This study is closed
Investigator
Susheel Kodali, MD
Do You Qualify?
Do you have symptomatic, severe, calcific aortic stenosis? Yes No
Are you at low risk for open-heart surgery for aortic valve replacement? Yes No
Will you be 65 years of age or older at time of consent? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Lauren Privitera
lp2183@cumc.columbia.edu
212-342-3488
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE